Tumor-targeted delivery of TAT-Apoptin fusion gene using Escherichia coli Nissle 1917 to colorectal cancer

Medical Hypotheses

Volumn 76, Issue 4, 2011, Pages 533-534

  Zhou, Suna ^a   Zhang, Mingxin ^a   Wang, Jiansheng ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL VECTOR; HYBRID PROTEIN; TAT APOPTIN FUSION PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GENE THERAPY; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ESCHERICHIA COLI; FUSION GENE; HUMAN; MOLECULARLY TARGETED THERAPY; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY;

ARTIFICIAL GENE FUSION; CAPSID PROTEINS; COLORECTAL NEOPLASMS; ESCHERICHIA COLI; GENE THERAPY; HUMANS; PROBIOTICS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

ESCHERICHIA COLI NISSLE 1917;

EID: 79952313887     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.12.010     Document Type: Article

References (14)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18:581-592.
2. Malchow H.A. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?. J Clin Gastroenterol 1997, 25:653-658.
3. Kruis W., Fric P., Pokrotnieks J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617-1623.
4. Westendorf A.M., Gunzer F., Deppenmeier S., et al. Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol 2005, 43:373-384.
5. Schultz M., Watzl S., Oelschlaeger T.A., et al. Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo. J Microbiol Methods 2005, 61:389-398.
6. Grozdanov L., Raasch C., Schulze J., et al. Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. Bacteriology 2004, 186:5432-5441.
7. Stritzker J., Weibel S., Hill P.J., Oelschlaeger T.A., Goebel W., Szalay A.A. Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice. Int J Med Microbiol 2007, 297:151-162.
8. Rao S., Hu S., McHugh L., et al. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci USA 2005, 102:11993-11998.
9. Danen-van Oorschot A.A., van Der Eb A.J., Noteborn M.H. The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J Virol 2000, 74:7072-7078.
10. Schoop R.A., Baatenburg de Jong R.J., Noteborn M.H. Apoptin induces apoptosis in an oral cancer mouse model. Cancer Biol Ther 2008, 7:1368-1373.
11. Schoop R.A., Verdegaal E.M., de Jong R.J., Noteborn M.H. Apoptin enhances radiation-induced cell death in poorly responding head and neck squamous cell carcinoma cells. Basic Clin Pharmacol Toxicol 2010, 106:130-134.
12. Danen-Van Oorschot A.A., Fischer D.F., Grimbergen J.M., et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci USA 1997, 94:5843-5847.
13. Vivès E., Brodin P., Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997, 272:16010-16017.
14. Guelen L., Paterson H., Gäken J., Meyers M., Farzaneh F., Tavassoli M. TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 2004, 23:1153-1165.